Fundaro Paolo 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Jun 1, 2021
Insider Transaction Report
Form 4
Fundaro Paolo
Director
Transactions
- Award
Common Stock
2021-05-27+7,029→ 28,057 total - Award
Option to Purchase Common Stock
2021-05-27+12,089→ 12,089 totalExercise: $17.08Exp: 2031-05-27→ Common Stock (12,089 underlying)
Holdings
- 4,000,000(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders.
- [F2]These shares are held by Genextra S.p.A. ("Genextra"). Mr. Fundaro is the Chief Executive Officer of Genextra. He disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any.
- [F3]All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders.